Our findings position ACTN1 as a pivotal modulator of β-catenin signaling in HNSCC cells, in alignment with our anticipation of ACTN1 as a central mediator of cisplatin resistance in HNSCC. This evidence concerns the gene ACTN1 and head and neck squamous cell carcinoma.